Keywords: پایان درمان; health insurance claims; ACE; Angiotensin-converting enzyme; CNS; Central nervous system; EOT; End of treatment; RR; Risk ratio;
مقالات ISI پایان درمان (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: پایان درمان; FLINT; NAFLD; Direct Comparison; Non-Invasive; AUROC; area under receiving operating curve; CI; confidence interval; CRN; clinical research network; EOT; end of treatment; MRI; magnetic resonance imaging; NAFLD; nonalcoholic fatty liver disease; NASH; non
Keywords: پایان درمان; Topical Corticosteroid; Esophageal Eosinophil; Symptom Score; Clinical Trial; AE; adverse event; CSS; Clinical Symptom Score; DSQ; Dysphagia Symptom Questionnaire; EoE; eosinophilic esophagitis; EOT; end of treatment; FDA; Food and Drug Administration; GE
Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals
Keywords: پایان درمان; HCV; RASs; DAA; Virologic Treatment Failure; DAA; direct-acting antiviral; DCV; daclatasvir; EOT; end of treatment; GT; genotype; HCV; hepatitis C virus; LDV; ledipasvir; NS; nonstructural protein; PCR; polymerase chain reaction; PEG IFN; pegylated interf
Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection
Keywords: پایان درمان; Routine Clinical Practice; Direct-Acting Antiviral Agents; Cirrhosis; Genotype 4; DAA; direct-acting antiviral agent; EOT; end of treatment; GT; genotype; HCV; hepatitis C virus; LDV; ledipasvir; OMV; ombitasvir; PTV; paritaprevir; r; ritonavir; RBV; riba
Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis
Keywords: پایان درمان; PDCD1; Immune Regulation; Response To Treatment; Liver Disease; BAFF; B-cell-activating factor of the tumor necrosis factor family; BR3; B-lymphocyte stimulator receptor 3; CV; cryoglobulinemia vasculitis; DAA; direct-acting antiviral; EOT; end of treat
The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis
Keywords: پایان درمان; CF; cystic fibrosis; COPD; chronic obstructive pulmonary disease; DPI; dry powder for inhalation; EOS; end of study; EOT; end of treatment; FAS; full analysis set; FEV1; forced expiratory volume in 1Â s; FVC; forced vital capacity; MIC; minimum inhibitory
Long-Term Safety and Efficacy of Solifenacin in Children and Adolescents with Overactive Bladder
Keywords: پایان درمان; adolescent; child; urinary incontinence; urinary bladder; overactive; solifenacin succinate; AE; adverse event; CNS; central nervous system; DBP; diastolic blood pressure; ECG; electrocardiogram; EoT; end of treatment; FAS; full analysis set; OAB; overact
Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection
Keywords: پایان درمان; Genetics; Liver Cancer; Mutation; Metalloprotease; AFP; α-fetoprotein; anti-HBc; antibody to hepatitis B core antigen; BMP1; bone morphogenetic protein 1; CCl4; carbon tetrachloride; CDAA; choline-deficient L-amino acid-defined; CHC; chronic hepatitis C;
Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study
Keywords: پایان درمان; AE; adverse events; DAAs; direct-acting antiviral agents; DCV; daclatasvir; EOT; end of treatment; GFR; glomerular filtration rate; HCV; hepatitis C virus; HIV; human immunodeficiency virus; IMS; immunosuppressive; LLOQ; lower limit of quantification; LT;
Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study
Keywords: پایان درمان; ADV; adefovir; AEs; adverse events; ALT; alanine aminotransferase; BMI; body mass index; CHB; chronic hepatitis B; EOF; end of follow-up; EOT; end of treatment; ETV; entecavir; HBV; hepatitis B virus; HBeAg; hepatitis B e antigen; HBeAb; hepatitis B e ant
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy
Keywords: پایان درمان; HCV; hepatitis C virus; DAA; direct-acting antivirals; SVR; sustained virological response; MELD; model for end-stage liver disease; HCC; hepatocellular carcinoma; BCLC; Barcelona Clinic Liver Cancer group; LOD; limit of detection; EOT; end of treatment;
Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function
Keywords: پایان درمان; Immune Regulation; NS5A Inhibitor; NS3 Inhibitor; ISG; APC; allophycocyanin; ASV; asunaprevir; CXCL; chemokine C-X-C motif ligand; DAA; direct-acting antiviral; DCV; daclatasvir; EMA; ethidium monoazide; EOT; end of treatment; FBS; fetal bovine serum; FIT
Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome
Keywords: پایان درمان; Chronic Delta Hepatitis; Pegylated Interferon Treatment; Treatment Outcome Prediction; On-Treatment HDV RNA; AD; adefovir dipivoxil; AUC; area under the curve; CDH; chronic delta hepatitis; CI; confidence interval; EOT; end of treatment; HBsAg; hepatitis
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial
Keywords: پایان درمان; AE; adverse event; Apo; apolipoprotein; BMI; body mass index; CV; cardiovascular; CVD; cardiovascular disease; EOT; end of treatment; EZE; ezetimibe; HbA1c; glycated hemoglobin A1c; HDL-C; high-density lipoprotein cholesterol; IQR; interquartile range; IT
Research ArticlePhase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure
Keywords: پایان درمان; PVT; portal vein thrombosis; TPO-R; thrombopoietin receptor; NASH; non-alcoholic steatohepatitis; MELD; model for end-stage liver disease; PK; pharmacokinetic; PD; pharmacodynamic; EOT; end of treatment; AE; adverse events; BMI; body mass index; CTP; Chil
Post-treatment Levels of α-Fetoprotein Predict Incidence of Hepatocellular Carcinoma After Interferon Therapy
Keywords: پایان درمان; ALT; Liver Cancer; Risk Factor; Response to Therapy; Outcome; AFP; α-fetoprotein; AFP24; α-fetoprotein levels at 24 weeks after the end of treatment; ALT; alanine aminotransferase; ALT24; alanine aminotransferase levels at 24 weeks after the end of trea
Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial
Keywords: پایان درمان; PROMISE; Chronic Hepatitis C; Drug; DAA; AE; adverse event; CI; confidence interval; DAA; direct-acting antiviral agent; EC50; median effective concentration; EOT; end of treatment; FDA; Food and Drug Administration; HCV; hepatitis C virus; IQR; interquar
Efficacy of Immunotherapy With TG4040, Peg-Interferon, and Ribavirin in a Phase 2 Study of Patients With Chronic HCV Infection
Keywords: پایان درمان; Vaccine; ELISpot; Immune Response; SVR24; AE; adverse event; cEVR; complete early virologic response; ETR; end of treatment; HCV; hepatitis C virus; ITT; intent-to-treat; LOD; limit of detection; MVA; modified vaccinia Ankara; PBMC; peripheral blood monon
Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial
Keywords: پایان درمان; Direct-Acting Antivirals; DAA; Clinical Trial; SVR24; AE; adverse event; EOT; end of treatment; FSS; Fatigue Severity Scale; HCV; hepatitis C virus; PegIFN; peginterferon-α2a; PegIFN-α; peginterferon-α; RBV; ribavirin; RVR; rapid virologic response; SV
Safety and Tolerability of Solifenacin Add-on Therapy to α-Blocker Treated Men With Residual Urgency and Frequency
Keywords: پایان درمان; urinary bladder; overactive; muscarinic antagonists; adrenergic alpha-antagonists; AE; adverse event; BOO; bladder outlet obstruction; BPH; benign prostatic hyperplasia; EOT; end of treatment; I-PSS; International Prostate Symptom Score; LUTS; lower urina
Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir
Keywords: پایان درمان; Prospective Clinical Trial; Replication Suppression; Liver Disease; ADV; adefovir dipivoxil; CHB; chronic hepatitis B; EOT; end of treatment; NUC; nucleos(t)ide analogue; OR; odds ratio; PCR; polymerase chain reaction; SR; sustained response; ULN; upper l
Research ArticlePredictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: Relationship of serum creatinine to hemodynamics
Keywords: پایان درمان; HRS; hepatorenal syndrome; MELD; model for end-stage liver disease; MAP; mean arterial pressure; SCr; serum creatinine; CI; confidence intervals; EOT; end of treatment;
Research ArticleVitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy
Keywords: پایان درمان; HCV; hepatitis C virus; SVR; sustained virologic response; RVR; rapid virologic response; EOT; end of treatment; EVR; virologic response, early virologic response; IFN; interferon; ALT; alanine aminotransferase; AST; aspartate aminotransferase; VDR; vitam
Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections
Keywords: پایان درمان; C209; VX-950; Liver Disease; Clinical Trial; AE; adverse event; EOT; end of treatment; HCV; hepatitis C virus; IL; interleukin; NS; nonstructural; Peg-IFN; peginterferon; PR; peginterferon alfa-2a (180 μg once weekly) and ribavirin (400 mg twice daily);
Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate
Keywords: پایان درمان; Adverse Effects of Hepatitis Therapy; Clinical Trial; Liver Disease; Blood Disorders; AE; adverse event; EOT; end of treatment; ESA; erythropoiesis-stimulating agent; Hb; hemoglobin; HCV; hepatitis C virus; IDEAL; Individualized Dosing Efficacy vs Flat Do
Impact of Erectile Dysfunction on Confidence, Self-Esteem and Relationship Satisfaction After 9 Months of Sildenafil Citrate Treatment
Keywords: پایان درمان; penis; impotence; sildenafil; quality of life; psychometrics; DBPC; double-blind, placebo controlled; ED; erectile dysfunction; EF; erectile function; EOT; end of treatment; IIEF; International Index of EF; OLE; open label extension; SEAR; Self-Esteem And